Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This situation generates substantial inefficiencies with many scanners being ...

Whole-body CD8+ T-cell PET imaging can detect spatial and temporal localization of CD8+ T cells. To obtain insight into early CD8+ T-cell response to immunotherapy in patients with melanoma, a highly ...

Nuclear medicine has evolved from a diagnostic-oriented speciality toward theranostics. Radionuclide therapy has become a booming business with newer radiopharmaceuticals and indications. Although the ...

Owen Witte, MD, is recognized for multiple seminal contributions over the past 50 years impacting our understanding of human leukemias, immune disorders, and epithelial cancers, which have defined new ...

This investigation examined the factors involved in predicting the responses of micrometastases to targeted 225Ac-based therapies and in optimizing these therapies through the use of cocktails of ...

International guidelines recommend salvage radiotherapy (sRT) as a curative treatment for men with biochemically recurrent prostate cancer after radical prostatectomy. Prostate-specific membrane ...

251452 Introduction: PSMA-targeted radioligand therapy (RLT) has shown remarkable efficacy in treating advanced metastatic castration-resistant prostate cancer (mCRPC). However, salivary gland ...

Radiopharmaceutical therapy (RPT) is entering a new era of personalization, driven by advances in molecular imaging, radiopharmaceutical development, and a growing body of clinical evidence linking ...

223Ra-dichloride (223Ra) is an approved therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic bone metastases. After an initial course of 6 ...

Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2)–targeted antibody–drug conjugate, demonstrated remarkable efficacy in previously treated patients with HER2-low ...

The gastrin-releasing peptide receptor (GRPR) is overexpressed in various cancers, including prostate cancer, breast cancer, small cell and non–small cell lung cancer, uterine and ovarian cancer, ...

The use of PET/CT with gastrin-releasing peptide receptor (GRPR) ligand [68Ga]Ga-AMTG has recently been shown to diagnose metastatic disease not detected by 18F-PSMA PET/CT in patients with metastatic ...